Search results for "BREAST"

showing 10 items of 1871 documents

A fully synthetic glycopeptide antitumor vaccine based on multiple antigen presentation on a hyperbranched polymer.

2014

For antitumor vaccines both the selected tumor-associated antigen, as well as the mode of its presentation, affect the immune response. According to the principle of multiple antigen presentation, a tumor-associated MUC1 glycopeptide combined with the immunostimulating T-cell epitope P2 from tetanus toxoid was coupled to a multi-functionalized hyperbranched polyglycerol by "click chemistry". This globular polymeric carrier has a flexible dendrimer-like structure, which allows optimal antigen presentation to the immune system. The resulting fully synthetic vaccine induced strong immune responses in mice and IgG antibodies recognizing human breast-cancer cells.

GlycerolSynthetic vaccinePolymersAntigen presentationEpitopes T-LymphocyteBreast NeoplasmsCancer VaccinesCatalysisEpitopeAntibodiesMiceImmune systemAntigenAntigens NeoplasmTetanus ToxoidOrganic chemistryAnimalsHumansAntigen PresentationbiologyChemistryOrganic ChemistryMucin-1ToxoidGlycopeptidesGeneral ChemistryGlycopeptideImmunologybiology.proteinMCF-7 CellsClick ChemistryFemaleAntibodyChemistry (Weinheim an der Bergstrasse, Germany)
researchProduct

Idiopathic granulomatous mastitis associated with risperidone: case report

2013

Granulomatous mastitis risperidone breast neoplasms
researchProduct

Automatic Seed Placement for Breast Lesion Segmentation on US Images

2012

Breast lesion boundaries have been mostly extracted by using conventional approaches as a previous step in the development of computer-aided diagnosis systems. Among these, region growing is a frequently used segmentation method. To make the segmentation completely automatic, most of the region growing methods incorporate automatic selection of the seed points. This paper proposes a new automatic seed placement algorithm for breast lesion segmentation on ultrasound images by means of assigning the probability of belonging to a lesion for every pixel depending on intensity, texture and geometrical constraints. The proposal has been evaluated using a set of sonographic breast images with acco…

Ground truthPixelbusiness.industryComputingMethodologies_IMAGEPROCESSINGANDCOMPUTERVISIONScale-space segmentationmedicine.diseaseSet (abstract data type)LesionBreast cancerRegion growingmedicineComputer visionSegmentationArtificial intelligencemedicine.symptombusiness
researchProduct

Lesion Segmentation in Breast Sonography

2010

Sonography is gaining popularity as an adjunct screening technique for assessing abnormalities in the breast This is particularly true in cases where the subject has dense breast tissue, wherein widespread techniques like Digital Mammography (DM) fail to produce reliable outcomes This article proposes a novel and fully automatic methodology for breast lesion segmentation in B-mode Ultra-Sound (US) images by utilizing region, boundary and shape information to cope up with the inherent artifacts present in US images The proposed approach has been evaluated using a set of sonographic images with accompanying expert-provided ground truth.

Ground truthmedicine.medical_specialtyLesion segmentationDigital mammographybusiness.industryBreast lesionComputingMethodologies_IMAGEPROCESSINGANDCOMPUTERVISIONmedicine.diseaseBreast sonographyBreast cancerFully automaticmedicineComputer visionSegmentationRadiologyArtificial intelligencebusiness
researchProduct

A randomized, open-label, multicentre, phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy based treatment strategy …

2017

TPS1115 Background: Although endocrine based therapy is recommended as first-line treatment in metastatic breast cancer (MBC) in patients with an HER2-/HR+ tumour up to 50% of the patients receive chemotherapy. Palbociclib (P) a CDK4/6 inhibitor improves PFS by 42% in endocrine sensitive and resistant HER2-/HR+ MBC when added to an endocrine therapy (ET). Patients included in clinical trials are often criticised not to be representative for real world breast cancer patients. Methods: Patients with first-line HER2-/HR+ MBC who are candidate for mono-chemotherapy will be eligible to be randomised 1:1 to receive either P plus ET per label or mono-chemotherapy per investigator´s choice with or…

GynecologyOncologyCancer Researchmedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentHER2 negativePalbociclibmedicine.diseaseMetastatic breast cancerOncologyHormone receptorInternal medicinemedicineEndocrine systemIn patientOpen labelbusinessJournal of Clinical Oncology
researchProduct

German Adjuvant Intergroup Node Positive (GAIN) study: A phase III trial to compare IDD-ETC versus EC-TX in patients with node-positive primary breas…

2014

1009 Background: Intense dose-dense (idd) epirubicin (E), paclitaxel (T), cyclophosphamide (C) (idd-ETC) resulted in a superior disease-free (DFS) and overall survival (OS) compared to conventional...

GynecologyOncologyCancer Researchmedicine.medical_specialtyCyclophosphamidebusiness.industrymedicine.medical_treatmentchemistry.chemical_compoundOncologyPaclitaxelchemistryInternal medicinemedicineOverall survivalIn patientskin and connective tissue diseasesbusinessPrimary breast cancerAdjuvantmedicine.drugEpirubicinJournal of Clinical Oncology
researchProduct

The effect of obesity on prognosis in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathologic subtyp…

2013

1031 Background: According to observational studies, obesity is an unfavourable prognostic factor in breast cancer (BC), regardless of menopausal status and treatment received. Information collected in clinical trials should confirm this effect and serves to test its homogeneity by pathologic subtype. Methods: We retrospectively analysed 5,683 operable BC patients enrolled in four randomized clinical trials (GEICAM/9906, 9805, 2003–02, and BCIRG 001) evaluating adjuvant anthracyclines and taxanes. Our primary aim was to assess the prognostic effect of body mass index (BMI) on disease recurrence, breast cancer mortality (BCM), and overall mortality (OM). A secondary aim was to detect differ…

GynecologyOncologyCancer Researchmedicine.medical_specialtyPrognostic factorbusiness.industrymedicine.medical_treatmentmedicine.diseaseObesityBreast cancerOncologyInternal medicinemedicineObservational studybusinessAdjuvantJournal of Clinical Oncology
researchProduct

Abstract CT020: MERIT: introducing individualized cancer vaccines for the treatment of TNBC - a phase I trial

2016

Abstract The majority of metastatic cancers remain incurable since the current methods of treatment often fail to target the heterogeneous nature of each individual patient's tumor. Personalized approaches targeting each individual patient's tumor may therefore bring significant improvements. The Mutanome Engineered RNA Immuno-Therapy (MERIT) consortium will clinically validate a pioneering RNA-based immunotherapy concept for the treatment of triple negative breast cancer (TNBC) by targeting shared tumor antigens and individual neo-antigens in TNBC patients. MERIT combines two personalized treatment concepts: (i) treatment with vaccines containing “off-the-shelf” mRNAs selected from a pre-s…

GynecologyOncologyCancer Researchmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentCancerImmunotherapymedicine.diseaseVaccinationClinical trialRadiation therapyBreast cancerOncologyDrug developmentInternal medicinemedicinebusinessTriple-negative breast cancerCancer Research
researchProduct

Outcome Prediction in Node-Negative Breast Cancer Based on ASCO-Recommended Biomarkers uPA/PAI-1 Using the Final 10-Year Analysis of the Randomized M…

2009

Abstract Background: Based on interim analysis of Chemo N0, the first prospective multicenter randomized clinical trial using biomarkers uPA/PAI-1 for risk stratification and chemotherapy selection in N0 breast cancer, uPA/PAI-1 are now recommended for routine use by ASCO and AGO guidelines. Final 10-year follow-up of Chemo N0 has validated the clinically relevant long-term prognostic and predictive impact of uPA/PAI-1 in N0 breast cancer. To quantify the clinical utility of this impact, outcomes in subgroups defined by these biomarkers were compared to predictions of Adjuvant Online™, the leading validated tool based on established clinical factors. Methods: In Chemo N0, patients (n=647, 1…

GynecologyOncologyCancer Researchmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentCancerInterim analysismedicine.diseaselaw.inventionClinical trialBreast cancerOncologyRandomized controlled triallawInternal medicineEpidemiologyAdjuvant therapyMedicinebusinessAdjuvantCancer Research
researchProduct

The HERBA trial: a retrospective study on patients (pts) with HER2-positive (HER2+ve) breast cancer (BC) and brain metastases (BMs)

2017

GynecologyOncologymedicine.medical_specialtyBreast cancerOncologybusiness.industryInternal medicinemedicineRetrospective cohort studyHematologymedicine.diseasebusinessER2-positive (HER2+ve) breast cancer (BC) brain metastases (BMs)
researchProduct